Navigation Links
Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences, Inc., a specialty dermatology company, today announced the publication of a paper in the March 9, 2007 issue of the journal Cell by its co-founder and board member, David E. Fisher, M.D., Ph.D., that identifies two new functions for an important protein, p53, in the pigmentation of skin. Fisher's study shows that in addition to its function as a tumor suppressor in other cancers in the body, p53 also plays a key role in prompting the skin to tan in response to ultraviolet light from the sun. By promoting tanning, p53 deters the development of the skin cancer melanoma, which is increasing in incidence faster than any other cancer in the world.

Fisher's research also shows that p53 causes the production of an endorphin after ultraviolet exposure, and this may modulate sensation in the skin in a manner that influences behaviors, possibly including sun-seeking behaviors.

For Magen BioSciences, the study in Cell provides important proof of concept for the company's approach to identify and develop therapeutic treatments for pigmentation disorders.

"We know that people who tan easily or have dark pigmentation are far less likely to develop melanoma," said David Fisher, with the Dana-Faber Cancer Institute. "This study suggests that p53, one of the best-known tumor-suppressor proteins in our body, goes into action when skin cells experience UV exposure, prompting the skin to tan as a defensive mechanism against DNA damage and at the same time creating endorphins that may alter sensation or even behavior."

"Dr. Fisher's discovery of this new function for a well-known protein sheds new light on the mechanism and function of tanning," said Brian Gallagher, Ph.D., Magen's president and chief executive officer. "This discovery will help Magen BioSciences identify lead compounds and develop therapeutic treatments for disfiguring dermato logical pigmentation disorders such as vitiligo, melasma, solar lentigos and post-inflammation hyperpigmentation."

About Magen BioSciences

Magen BioSciences is a specialty pharmaceutical company focused on developing proprietary medical therapies for the dermatology market. Magen was co-founded in March 2006 by Richard Aldrich, David Fisher, M.D. Ph.D., Phillip Sharp, Ph.D., David Shaw, Christopher Walsh, Ph.D. and Christoph Westphal, M.D., Ph.D. Investors include Alexandria Real Estate, ARCH Venture Partners, Highland Capital Partners, IDG Ventures, Lux Capital, QVT Financial LP, TVM Capital and Venrock Associates.

Contact

for Magen BioSciences, Inc.
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com
www.magenbiosciences.com


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):